Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46

Benzinga Newsdesk www.benzinga.com Negative 60.0%

Neg 60% Neu 0% Pos 0%

Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.